Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork CCRN Survey David Gaffney MDPhD Huntsman Cancer Institute University of Utah Cervix Cancer Education Symposium, , January 2019, South Africa
27 sites/12 countries; Response rate 100%! Ethiopia Addis Ababa St. Paul’s Hospital Ghana Uganda Chuang-Jhingran Kampala Kenya Nairobi Eldoret Nigeria Tanzania/URT Lagos Dar es Salaam Berek Mwanza Zambia Bugando Medical Center Lusaka Kilimanjaro Medical Center Chuang Zimbabwe Ocean Road Cancer Institute Malawi Bulawayo Blantyre Harare South Africa Stellenbosch DOH Namibia Pretoria UCT Windhoek UFS Botswana WITS Gabarone SMU PE Kalafong
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork 1. <1% to 90% 2. Most are low, 3 respondents were >50% Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork 28% Range: Unknown to 50% Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Average of 2.0 Linacs and 0.6 Cobalt machines per site (n=15). Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork If you have access to RT - For definitive radiotherapy at your site: (Average answer) How many external beam fractions are given? 22 What total dose is given? 47 Gy How many brachytherapy fractions? 3.6 Do you utilize MRI scans for brachytherapy? No What percentage of all patients receive radical radiotherapy with curative intent? 65% What percentage of patients receive concurrent chemotherapy? 73% For those not treated with curative intent, why did they not receive curative Late Stage treatment? On average, how many total elapsed days does it take to complete radiation therapy 53 days (external beam and brachytherapy from day 1 being the first radiation treatment)? Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork What percentage of patients with cervical 16% cancer at your center are early stage (IA-IB)? Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork What percentage of early stage cervical cancer patients treated with curative intent are 57% treated by surgery? Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork What is your preferred chemo regimen for recurrent Cervix Cancer? 14 12 10 8 6 4 2 0 Carboplatin Paclitaxel Cisplatin Adriamycin Taxol Taxane Chemoradiation Gemcitabine Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork What is your preferred chemo regimen for metastatic Cervix Cancer? 14 12 10 8 6 4 2 0 Carboplatin Paclitaxel Cisplatin Irenotican Taxol Taxane Chemoradiation Gemcitabine Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork How Many Cervix cancer clinical trials are opened at your site? other no yes 0 2 4 6 8 10 12 14 Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Cervix Cancer Education Symposium, , January 2019, South Africa
Gynecologic Ca Cancer In InterGroup Ce Cervix ix Ca Cancer Res esea earch Netw twork Thanks to Lindsay Burt MD and the CCRN Steering Committee for generating this survey Cervix Cancer Education Symposium, , January 2019, South Africa
Thank you
Recommend
More recommend